Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 7 Neoplasms 4 Breast Neoplasms 4 Recurrence 3 Colonic Neoplasms 3 Rectal Neoplasms 2 Neoplasm Metastasis 2 Tuberous Sclerosis 1 Seizures 1 Rectal Diseases 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neoplastic Cells, Circulating 1 Neoplasms by Site 1 Nasopharyngeal Carcinoma 1 NSCLC 1 Multiple Myeloma 1 Lung Neoplasms 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Inflammation 1 Gastrointestinal Neoplasms 1 Gastrointestinal Hemorrhage 1 Gastrointestinal Diseases 1 Epilepsy 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Colonic Diseases 1 Cognitive Dysfunction 1 Carcinoma, Squamous Cell 1

Interventions

Gefitinib 5 icotinib 4 Pemetrexed 4 Docetaxel 4 camrelizumab 3 apatinib 3 anlotinib 3 aflutinib 3 Erlotinib Hydrochloride 3 osimertinib 2 dacomitinib 2 Thalidomide 2 Radiosurgery 2 Drug Therapy 2 Carboplatin 2 Afatinib 2 trilaciclib 1 spartalizumab 1 pembrolizumab 1 nimotuzumab 1 famitinib 1 envafolimab 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 S 1 (combination) 1 Radiofrequency Ablation 1 Microphysiological Systems 1 Immune Checkpoint Inhibitors 1 Cisplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × NSCLC × Aspirin × Clear all

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡